New chemo combo tested for returning lymphoma
NCT ID NCT07389356
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase II trial will test two different drug combinations in 70 people whose diffuse large B-cell lymphoma has returned more than a year after initial treatment. One group gets a modified R-MINE regimen (rituximab, ifosfamide, mitoxantrone liposome, etoposide), the other gets R-GemOx (rituximab, gemcitabine, oxaliplatin). The goal is to see which combination works better at shrinking tumors and controlling the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Rituximab, ifosfamide, mitoxantrone liposome, etoposide (modified R-MINE) vs rituximab, gemcitabine, oxaliplatin (R-GemOx)
- What this could lead to
- If successful, this trial could identify a more effective chemotherapy regimen for patients whose diffuse large B-cell lymphoma has returned more than a year after initial treatment.
- What could go wrong
- This is a small, early-phase (phase II) study with only 70 participants, so results may not apply to all patients. Both regimens involve strong chemotherapy with significant side effects, and the trial has not yet started recruiting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DLBCL - DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Four-Pronged attack beat brain lymphoma?
- Can a new drug combo outsmart resistant lymphomas?
- Can a targeted drug boost standard chemo for aggressive lymphoma?
- Can a targeted drug combo outsmart an aggressive lymphoma?
- Can a reshaped chemo combo tame lymphoma with fewer side effects?
- New drug cocktail aims to outsmart aggressive blood cancer